2020
Response to Epigenetic Disruption in Tumor Suppressor of Hepatocellular Carcinoma (HCC)
Luna A, Wu Q, Hlady R, Sathyanarayan A, Rustgi V, Guarrera J, Robertson K, Liu C. Response to Epigenetic Disruption in Tumor Suppressor of Hepatocellular Carcinoma (HCC). The FASEB Journal 2020, 34: 1-1. DOI: 10.1096/fasebj.2020.34.s1.08693.Peer-Reviewed Original ResearchHepatocellular carcinomaCancer risk detectionInhibitor 5-aza-2'-deoxycytidineHepatocellular carcinoma detectionHepatocellular carcinoma patientsEpigenetic changesHepatocellular carcinoma tumorsHuh7.5 cellsImproved treatment optionsHCC cell linesGene promoter sitesStressed cellsTreatment optionsTumor formationEpigenetic disruptionEffective treatmentGenetic mutationsLiver cancerEpigenetic dysregulationTumorMethylation inhibitorSuppressor of hepatocellular carcinomaTumor pathwaysWestern blot showEpigenetic events
2011
Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF
Xing F, Persaud Y, Pratilas C, Taylor B, Janakiraman M, She Q, Gallardo H, Liu C, Merghoub T, Hefter B, Dolgalev I, Viale A, Heguy A, De Stanchina E, Cobrinik D, Bollag G, Wolchok J, Houghton A, Solit D. Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF dependence in melanomas harboring V600EBRAF. Oncogene 2011, 31: 446-457. PMID: 21725359, PMCID: PMC3267014, DOI: 10.1038/onc.2011.250.Peer-Reviewed Original ResearchConceptsHeterogeneity of clinical outcomesSpectrum of genetic alterationsLoss of p16INK4aDiversity of clinical phenotypesLoss of RB1Prevent tumor formationMEK-selective inhibitorsRB1 tumor suppressorV600EBRAF mutationRB1 alterationsMutant BRAFClinical benefitMitogen-activated protein kinase pathwayClinical outcomesBRAF signalingGenetic alterationsGenomic alterationsOncogenic BRAFClinical phenotypePTEN inactivationProtein kinase pathwayCritical oncogenesTumor formationBRAFHuman cancers